190 related articles for article (PubMed ID: 30873608)
1. Phenotypic spectrum of NRXN1 mono- and bi-allelic deficiency: A systematic review.
Castronovo P; Baccarin M; Ricciardello A; Picinelli C; Tomaiuolo P; Cucinotta F; Frittoli M; Lintas C; Sacco R; Persico AM
Clin Genet; 2020 Jan; 97(1):125-137. PubMed ID: 30873608
[TBL] [Abstract][Full Text] [Related]
2. Homozygous exonic and intragenic NRXN1 deletion presenting as either West syndrome or autism spectrum disorder in two siblings.
Aksu Uzunhan T; Ayaz A
Clin Neurol Neurosurg; 2022 Mar; 214():107141. PubMed ID: 35101781
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of intragenic
Cosemans N; Vandenhove L; Vogels A; Devriendt K; Van Esch H; Van Buggenhout G; Olivié H; de Ravel T; Ortibus E; Legius E; Aerssens P; Breckpot J; R Vermeesch J; Shen S; Fitzgerald J; Gallagher L; Peeters H
J Med Genet; 2020 May; 57(5):347-355. PubMed ID: 31932357
[TBL] [Abstract][Full Text] [Related]
4. NRXN1 deletion syndrome; phenotypic and penetrance data from 34 families.
Al Shehhi M; Forman EB; Fitzgerald JE; McInerney V; Krawczyk J; Shen S; Betts DR; Ardle LM; Gorman KM; King MD; Green A; Gallagher L; Lynch SA
Eur J Med Genet; 2019 Mar; 62(3):204-209. PubMed ID: 30031152
[TBL] [Abstract][Full Text] [Related]
5. Further insight into the neurobehavioral pattern of children carrying the 2p16.3 heterozygous deletion involving NRXN1: Report of five new cases.
Alfieri P; Scibelli F; Sinibaldi L; Valeri G; Caciolo C; Novello RL; Novelli A; Digilio MC; Tartaglia M; Vicari S
Genes Brain Behav; 2020 Sep; 19(7):e12687. PubMed ID: 32658356
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of NRXN1 deletions from 19,263 clinical microarray cases identifies exons important for neurodevelopmental disease expression.
Lowther C; Speevak M; Armour CM; Goh ES; Graham GE; Li C; Zeesman S; Nowaczyk MJ; Schultz LA; Morra A; Nicolson R; Bikangaga P; Samdup D; Zaazou M; Boyd K; Jung JH; Siu V; Rajguru M; Goobie S; Tarnopolsky MA; Prasad C; Dick PT; Hussain AS; Walinga M; Reijenga RG; Gazzellone M; Lionel AC; Marshall CR; Scherer SW; Stavropoulos DJ; McCready E; Bassett AS
Genet Med; 2017 Jan; 19(1):53-61. PubMed ID: 27195815
[TBL] [Abstract][Full Text] [Related]
7. Investigation of NRXN1 deletions: clinical and molecular characterization.
Dabell MP; Rosenfeld JA; Bader P; Escobar LF; El-Khechen D; Vallee SE; Dinulos MB; Curry C; Fisher J; Tervo R; Hannibal MC; Siefkas K; Wyatt PR; Hughes L; Smith R; Ellingwood S; Lacassie Y; Stroud T; Farrell SA; Sanchez-Lara PA; Randolph LM; Niyazov D; Stevens CA; Schoonveld C; Skidmore D; MacKay S; Miles JH; Moodley M; Huillet A; Neill NJ; Ellison JW; Ballif BC; Shaffer LG
Am J Med Genet A; 2013 Apr; 161A(4):717-31. PubMed ID: 23495017
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions.
Schaaf CP; Boone PM; Sampath S; Williams C; Bader PI; Mueller JM; Shchelochkov OA; Brown CW; Crawford HP; Phalen JA; Tartaglia NR; Evans P; Campbell WM; Tsai AC; Parsley L; Grayson SW; Scheuerle A; Luzzi CD; Thomas SK; Eng PA; Kang SH; Patel A; Stankiewicz P; Cheung SW
Eur J Hum Genet; 2012 Dec; 20(12):1240-7. PubMed ID: 22617343
[TBL] [Abstract][Full Text] [Related]
9. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1.
Gregor A; Albrecht B; Bader I; Bijlsma EK; Ekici AB; Engels H; Hackmann K; Horn D; Hoyer J; Klapecki J; Kohlhase J; Maystadt I; Nagl S; Prott E; Tinschert S; Ullmann R; Wohlleber E; Woods G; Reis A; Rauch A; Zweier C
BMC Med Genet; 2011 Aug; 12():106. PubMed ID: 21827697
[TBL] [Abstract][Full Text] [Related]
10. Neurexins and neuropsychiatric disorders.
Kasem E; Kurihara T; Tabuchi K
Neurosci Res; 2018 Feb; 127():53-60. PubMed ID: 29221905
[TBL] [Abstract][Full Text] [Related]
11. An increased burden of rare exonic variants in NRXN1 microdeletion carriers is likely to enhance the penetrance for autism spectrum disorder.
Cameli C; Viggiano M; Rochat MJ; Maresca A; Caporali L; Fiorini C; Palombo F; Magini P; Duardo RC; Ceroni F; Scaduto MC; Posar A; Seri M; Carelli V; Visconti P; Bacchelli E; Maestrini E
J Cell Mol Med; 2021 Mar; 25(5):2459-2470. PubMed ID: 33476483
[TBL] [Abstract][Full Text] [Related]
12. CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila.
Zweier C; de Jong EK; Zweier M; Orrico A; Ousager LB; Collins AL; Bijlsma EK; Oortveld MA; Ekici AB; Reis A; Schenck A; Rauch A
Am J Hum Genet; 2009 Nov; 85(5):655-66. PubMed ID: 19896112
[TBL] [Abstract][Full Text] [Related]
13. Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature.
Béna F; Bruno DL; Eriksson M; van Ravenswaaij-Arts C; Stark Z; Dijkhuizen T; Gerkes E; Gimelli S; Ganesamoorthy D; Thuresson AC; Labalme A; Till M; Bilan F; Pasquier L; Kitzis A; Dubourgm C; Rossi M; Bottani A; Gagnebin M; Sanlaville D; Gilbert-Dussardier B; Guipponi M; van Haeringen A; Kriek M; Ruivenkamp C; Antonarakis SE; Anderlid BM; Slater HR; Schoumans J
Am J Med Genet B Neuropsychiatr Genet; 2013 Jun; 162B(4):388-403. PubMed ID: 23533028
[TBL] [Abstract][Full Text] [Related]
14. Characterization of speech and language phenotype in children with NRXN1 deletions.
Brignell A; St John M; Boys A; Bruce A; Dinale C; Pigdon L; Hildebrand MS; Amor DJ; Morgan AT
Am J Med Genet B Neuropsychiatr Genet; 2018 Dec; 177(8):700-708. PubMed ID: 30358070
[TBL] [Abstract][Full Text] [Related]
15. Genetic insights and neurobiological implications from NRXN1 in neuropsychiatric disorders.
Hu Z; Xiao X; Zhang Z; Li M
Mol Psychiatry; 2019 Oct; 24(10):1400-1414. PubMed ID: 31138894
[TBL] [Abstract][Full Text] [Related]
16. [Prenatal diagnosis of partial deletion of NRXN1 gene with combined CNV-seq and qPCR assays].
Wang L; Shi P; Ren H; Xue S; Kong X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Nov; 39(11):1200-1204. PubMed ID: 36317203
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenia-associated NRXN1 deletions induce developmental-timing- and cell-type-specific vulnerabilities in human brain organoids.
Sebastian R; Jin K; Pavon N; Bansal R; Potter A; Song Y; Babu J; Gabriel R; Sun Y; Aronow B; Pak C
Nat Commun; 2023 Jun; 14(1):3770. PubMed ID: 37355690
[TBL] [Abstract][Full Text] [Related]
18. Cross-platform validation of neurotransmitter release impairments in schizophrenia patient-derived
Pak C; Danko T; Mirabella VR; Wang J; Liu Y; Vangipuram M; Grieder S; Zhang X; Ward T; Huang YA; Jin K; Dexheimer P; Bardes E; Mitelpunkt A; Ma J; McLachlan M; Moore JC; Qu P; Purmann C; Dage JL; Swanson BJ; Urban AE; Aronow BJ; Pang ZP; Levinson DF; Wernig M; Südhof TC
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34035170
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.
Jenkins A; Apud JA; Zhang F; Decot H; Weinberger DR; Law AJ
Neuropsychopharmacology; 2014 Aug; 39(9):2170-8. PubMed ID: 24633560
[TBL] [Abstract][Full Text] [Related]
20. Mutation screening of the neurexin 1 gene in thai patients with intellectual disability and autism spectrum disorder.
Yangngam S; Plong-On O; Sripo T; Roongpraiwan R; Hansakunachai T; Wirojanan J; Sombuntham T; Ruangdaraganon N; Limprasert P
Genet Test Mol Biomarkers; 2014 Jul; 18(7):510-5. PubMed ID: 24832020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
